Seeking Alpha

Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from...

Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from drug partner Merck (MRK), which started a late-stage study of THLD's pancreatic cancer drug. TH-302 is an investigational hypoxia-targeted drug designed to be activated under severe tumor hypoxic conditions, a hallmark of many cancers.
Comments (1)
  • biochemist
    , contributor
    Comments (353) | Send Message
     
    SA Editors - Merck KgA (MRK.DE), the German company, is partnered with THLD on TH-302, not MRK the US pharma.
    25 Jan 2013, 10:52 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|